Arthrosurface said today that it paid an unspecified amount to acquire an acellular dermal stabilization device technology from Wasas LLC.
Derived from human tissue, acellular dermis is made using a process that removes cells but retains portions of the extracellular matrix to create dermal allografts.
The deal includes the patent rights for the technology, which Franklin, Mass.-based Arthrosurface plans to develop and market “a platform of novel methods to be used to correct orthopedic challenges” for several indications. Wasas is based in Ft. Lauderdale.
“The availability of this allograft to Arthrosurface will allow us to execute on a pipeline of clinical applications that we have identified with our surgeon partners over the past several years,” CEO Steve Ek said in prepared remarks.
In March 2014 Arthrosurface won 510(k) clearance from the FDA for its ToeMotion Total Toe fixation system.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.